Anamay Biotech (opc) Private Limited is an Indian Non-Government Company. It's a one person company company and is classified as'company limited by shares'. Company's authorized capital stands at Rs 2 ...

Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug ...

Ajooni Biotech Limited was originally incorporated as a Private Limited Company with the name Ajooni Biotech Private Limited at Chandigarh on 17th February, 2010. Consequent upon conversion of the ...

REHOVOT, Israel - Purple Biotech Ltd. (NASDAQ/TASE: PPBT), a clinical-stage biopharmaceutical company with a market capitalization of $6.07 million, today announced the appointment of Shai Lankry ...

About Purple Biotech Purple Biotech Ltd. (NASDAQ/TASE: PPBT) is a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance.

Windlas Biotech Limited (formerly known as Windlas Biotech Private Limited) was incorporated in 2001. The Company convertedfrom a Private Limited Company to a Public Limited Company and the name ...

Wolf and Dr. Rubinek team at Tel Aviv University and Sourasky Medical Center REHOVOT, Israel, April 16, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech ...

View today's HOB Biotech Group Corp Ltd stock price and latest 688656 news and analysis. Create real-time notifications to follow any changes in the live stock price.

(RTTNews) - Purple Biotech Ltd. (PPBT, PPBT.TA), an Israeli clinical-stage biotechnology company, on Monday announced that it has appointed Shai Lankry as its Chief Financial Officer. Lankry has ...

Purple Biotech Ltd. has appointed Shai Lankry as its new Chief Financial Officer, bringing over 20 years of experience in financial leadership within the biotech and healthcare sectors.

With the walls quickly closing in, Kronos Bio has accepted a buyout from notorious biotech acquirer Concentra Biosciences. Tang Capital Partners’ Concentra inked a definitive deal to acquire ...